Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMO 103

X
Drug Profile

OMO 103

Alternative Names: OMO-103; Omomyc

Latest Information Update: 11 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peptomyc; Vall d-Hebron Research Institute
  • Developer Peptomyc
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Adenocarcinoma
  • Preclinical Breast cancer; Colorectal cancer
  • No development reported Lung cancer

Most Recent Events

  • 31 Aug 2023 Phase-I clinical trials in Adenocarcinoma (Combination therapy, Metastatic disease, Treatment-naive, Late-stage disease, First-line therapy) in Spain (IV) (NCT06059001)
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Lung-cancer in Spain (IV)
  • 27 Jul 2023 Peptomyc plans phase-Ib trial for Adenocarcinoma (Combination therapy, First-line therapy, Metastatic disease) in Spain (Parenteral) in Q3 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top